ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Davisite
|
18K |
6.1M |
32 |
13:21 |
13:21 |
ASX - By Stock
|
18K
|
6.1M
|
32
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Updated Strategy and Investor Presentation
|
|
Davisite
|
338 |
67K |
25 |
12:39 |
12:39 |
ASX - By Stock
|
338
|
67K
|
25
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Davisite
|
18K |
6.1M |
44 |
12:21 |
12:21 |
ASX - By Stock
|
18K
|
6.1M
|
44
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Updated Strategy and Investor Presentation
|
|
Davisite
|
338 |
67K |
71 |
06:43 |
06:43 |
ASX - By Stock
|
338
|
67K
|
71
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Updated Strategy and Investor Presentation
|
|
Davisite
|
338 |
67K |
30 |
06:21 |
06:21 |
ASX - By Stock
|
338
|
67K
|
30
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Updated Strategy and Investor Presentation
|
|
Davisite
|
338 |
67K |
53 |
06:16 |
06:16 |
ASX - By Stock
|
338
|
67K
|
53
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Zantrene highly effective in EMD AML Mouse Model
|
|
Davisite
|
110 |
39K |
20 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
110
|
39K
|
20
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
43 |
30/11/23 |
30/11/23 |
General
|
9.7K
|
3.3M
|
43
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Zantrene highly effective in EMD AML Mouse Model
|
|
Davisite
|
110 |
39K |
37 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
110
|
39K
|
37
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
22 |
30/11/23 |
30/11/23 |
General
|
9.7K
|
3.3M
|
22
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
32 |
30/11/23 |
30/11/23 |
General
|
9.7K
|
3.3M
|
32
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Phase III CLARIFY trial in prostate cancer commences
|
|
Davisite
|
14 |
2.6K |
14 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
14
|
2.6K
|
14
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: undetectable PSA level with Cu-67 SAR-bisPSMA
|
|
Davisite
|
24 |
5.1K |
29 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
24
|
5.1K
|
29
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Phase III CLARIFY trial in prostate cancer commences
|
|
Davisite
|
14 |
2.6K |
13 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
14
|
2.6K
|
13
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Phase III CLARIFY trial in prostate cancer commences
|
|
Davisite
|
14 |
2.6K |
14 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
14
|
2.6K
|
14
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
100 |
30/11/23 |
30/11/23 |
General
|
9.7K
|
3.3M
|
100
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
0 |
30/11/23 |
30/11/23 |
General
|
9.7K
|
3.3M
|
0
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
2 |
30/11/23 |
30/11/23 |
General
|
9.7K
|
3.3M
|
2
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
5 |
30/11/23 |
30/11/23 |
General
|
9.7K
|
3.3M
|
5
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
16 |
30/11/23 |
30/11/23 |
General
|
9.7K
|
3.3M
|
16
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
2 |
30/11/23 |
30/11/23 |
General
|
9.7K
|
3.3M
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Updated Strategy and Investor Presentation
|
|
Davisite
|
338 |
67K |
69 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
338
|
67K
|
69
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Prospectus
|
|
Davisite
|
226 |
42K |
27 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
226
|
42K
|
27
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Updated Strategy and Investor Presentation
|
|
Davisite
|
338 |
67K |
12 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
338
|
67K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Updated Strategy and Investor Presentation
|
|
Davisite
|
338 |
67K |
23 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
338
|
67K
|
23
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Updated Strategy and Investor Presentation
|
|
Davisite
|
338 |
67K |
52 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
338
|
67K
|
52
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
16 |
29/11/23 |
29/11/23 |
General
|
9.7K
|
3.3M
|
16
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology 2023 Chair's Address & AGM Presentation
|
|
Davisite
|
75 |
16K |
15 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
75
|
16K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology 2023 Chair's Address & AGM Presentation
|
|
Davisite
|
75 |
16K |
47 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
75
|
16K
|
47
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: SECuRE theranostic prostate cancer trial progresses
|
|
Davisite
|
8 |
1.7K |
16 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
8
|
1.7K
|
16
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Prospectus
|
|
Davisite
|
226 |
42K |
5 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
226
|
42K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Prospectus
|
|
Davisite
|
226 |
42K |
12 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
226
|
42K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Prospectus
|
|
Davisite
|
226 |
42K |
16 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
226
|
42K
|
16
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
21 |
29/11/23 |
29/11/23 |
General
|
9.7K
|
3.3M
|
21
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Prospectus
|
|
Davisite
|
226 |
42K |
10 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
226
|
42K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Prospectus
|
|
Davisite
|
226 |
42K |
15 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
226
|
42K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Prospectus
|
|
Davisite
|
226 |
42K |
22 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
226
|
42K
|
22
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology 2023 Chair's Address & AGM Presentation
|
|
Davisite
|
75 |
16K |
10 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
75
|
16K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology 2023 Chair's Address & AGM Presentation
|
|
Davisite
|
75 |
16K |
24 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
75
|
16K
|
24
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology 2023 Chair's Address & AGM Presentation
|
|
Davisite
|
75 |
16K |
61 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
75
|
16K
|
61
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology 2023 Chair's Address & AGM Presentation
|
|
Davisite
|
75 |
16K |
22 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
75
|
16K
|
22
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology 2023 Chair's Address & AGM Presentation
|
|
Davisite
|
75 |
16K |
38 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
75
|
16K
|
38
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology 2023 Chair's Address & AGM Presentation
|
|
Davisite
|
75 |
16K |
48 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
75
|
16K
|
48
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology 2023 Chair's Address & AGM Presentation
|
|
Davisite
|
75 |
16K |
40 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
75
|
16K
|
40
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology 2023 Chair's Address & AGM Presentation
|
|
Davisite
|
75 |
16K |
36 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
75
|
16K
|
36
|
|
ASX - By Stock
|
ORR |
Re:
Ann: PRU: Perseus acquires 15.03% interest in Orecorp
|
|
Davisite
|
53 |
13K |
0 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
53
|
13K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: 2023 AGM Chair's Address to Shareholders
|
|
Davisite
|
19 |
4.7K |
17 |
26/11/23 |
26/11/23 |
ASX - By Stock
|
19
|
4.7K
|
17
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
52 |
26/11/23 |
26/11/23 |
General
|
9.7K
|
3.3M
|
52
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
26 |
26/11/23 |
26/11/23 |
General
|
9.7K
|
3.3M
|
26
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
9.7K |
3.3M |
46 |
26/11/23 |
26/11/23 |
General
|
9.7K
|
3.3M
|
46
|
|